Table 2 Drugs for the treatment and/or prevention of Covid-19. Fifteen candidate drugs target more than one druggable control hub, among which two belong to immune-related agents (in orange), nine are dietary supplements (in green), and two are gonadal hormones (in blue). The drugs with “*” are under clinical trial for treating Covid-19. Detailed information is available in Table S5
From: Total network controllability analysis discovers explainable drugs for Covid-19 treatment
Drug | Control hub Number | Control hub |
|---|---|---|
Fostamatinib* | 10 | COQ8A, CLK3, CLK2, YES1, BLK, PAK5, STK3, RIPK1, PKN1, CDK4 |
NADH* | 5 | CYB5R3, EHHADH, HIBADH, NDUFB7, IMPDH1 |
Calcium phosphate dihydrate | 3 | S100A13, PEF1, CATSPER1 |
Calcium Citrate | 3 | S100A13, PEF1, CATSPER1 |
Calcium Phosphate | 3 | S100A13, PEF1, CATSPER1 |
Conjugated estrogens* | 2 | SLC10A1, COMT |
Progesterone* | 2 | SLC10A1, SULT2B1 |
Phenethyl Isothiocyanate | 5 | HNRNPF, TPM1, |
Ademetionine | 3 | COMT, GNMT, MAT2A |
Copper | 2 | AHCY, CYB5R3 |
Aspartic acid | 2 | ASPH, ACY3 |
Methionine | 2 | GLUL, MAT2A |
Citric acid | 2 | HGS, GNMT |
Liothyronine | 2 | PCNA, SLC10A1 |
Liotrix | 2 | SLC10A1, SLC16A2 |